AstraZeneca Announces Positive Results for Enhertu in Treating HER2 Breast Cancer

Via Peters

Trastuzumab deruxtecan demonstrated clinically meaningful and statistically significant improvements in overall and progression-free survival, the company says. AstraZeneca announced positive results from the DESTINY-Breast04 phase 3 trial of trastuzumab deruxtecan (Enhertu, AstraZeneca, Daiichi Sankyo) in individuals with HER2-low unresectable and/or metastatic breast cancer, regardless of hormone receptor (HR) status versus […]